Northwestern University Feinberg School of Medicine

Rintaro Hashizume Lab

Selected Publications

Zhou J, Tien AC, Alberta JA, Ficarro SB, Griveau A, Sun Y, Deshpande JS, Card JD, Morgan-Smith M, Michowski W, Hashizume R, James CD, Ligon KL, Snider WD, Sicinski P, Marto JA, Rowitch DH, Stiles CD. A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 Mar 28;18(13):3167-3177. doi: 10.1016/j.celrep.2017.03.003.

Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM2, Kelleher NL, James CD, Shilatifard A. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Feb 27. doi: 10.1038/nm.4296. [Epub ahead of print]

Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. Journal of Neuro-Oncology. 2016 Nov 15. [Epub ahead of print]. PMID: 27848137

Rintaro Hashizume, MD/PhD has co-authored an article for the July 2016 edition of Neuro-Oncology titled ‘Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth’

See the contribution of Rintaro Hashizume, MD/PhD to the Atlas of Science titled ‘In vivo imaging of immunotherapeutic glioma model

Science Advances publishes “Mutations in chromatin machinery and pediatric high-grade glioma” authored by Rishi R. Lulla, MD, Amanda Muhs Saratsis, MD and Rintaro Hashizume, MD/PhD. The article summarizes the current state of knowledge of chromatin modification in pediatric high grade glioma.

A new video, Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma, published in the Journal of Visualized Experiments demonstrates proper techniques for monitoring intracranial tumor growth using in vivo bioluminescence imaging, and to verify the utility of luciferase-modified GL261 cells for studying tumor immunology and immunotherapeutic approaches for treating glioblastoma.


Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Koeck K, Sidorov M, Hashizume R, Ozawa T, Berger MS, Nicolaides T, James CD, Petritsch C. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells. Cancer Research. 2015 Dec 15;75(24):5355-66. PMID: 26573800. Epub 2015 Nov 16.
 
Dasgupta T, Olow AK, Yang X, Hashizume R, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, David James C, Mueller S, Haas-Kogan DA. Survival advantage combining a BRAF inhibitor and radiation in BRAF-V600E-mutant glioma. J Neurooncol. 2015 Sep 18. [Epub ahed of print]. PMID: 26384810

News/Events

Rintaro Hashizume, MD/PhD is part of a collaborative research team that has found a molecule that stops the growth of an aggressive pediatric brain tumor. Their findings are featured in the Northwestern Medicine News, and Nature Medicine has an advanced online publication of their research.

Rintaro Hashizume, MD/PhD will be presenting a special lecture entitled ‘Epigenetic Targeting therapy for diffuse intrinsic pontine glioma’ at JSPN in Tsukuba, Japan on June 23rd. Click here for the program.

Find out about the research work of the Rintaro Hashizume Lab presented on the Open Science DB

Amanda Saratsis, MD, Rintaro Hashizume, MD/PhD, and C. David James, PhD, and others are featured as part of an interdisciplinary team of physicians and researchers combating pediatric brain tumors in Lurie’s Heroes Spring 2016 issue

Irina Balyasnikova, PhD and Rintaro Hashizume, MD/PhD, have been awarded an IDP/Sherman Fairchild Research Innovation Challenge for their research titled ’Developing a Non-Invasive Stem Cell-Based Approach to Treatment of Pediatric Brainstem Glioma’

Northwestern and Lurie Children’s Hospital ‘Dream Team’, featuring Rintaro Hasizume, MD/PhD, profiled by CBS2 Chicago in their fight against pediatric brain tumors

Rintaro Hashizume, MD/PhD, Amanda Saratsis, MD, and C. David James, PhD part of pediatric brain tumor ‘Dream Team’

Dr. Hashizume is invited to lecture in the Department of Pharmacology and NBTI meeting at Lurie Cancer Center, February, 2016.
 
Dr. Hashizume is invited to lecture in the Department of Cell Modulation Institute of Molecular Embryology at Kumamoto University, Kumamoto, Japan, December 2015.
 
Dr. Quanhong Grace Ma will be presented her work histone demethylase inhibition in combination with radiation for diffuse intrinsic pontine gliomas in the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-­‐Oncology at San Antonio, Texas in November, 2015.

Targeting an Ion Channel to Treat Common Pediatric Brain Tumor article details the Hashizume Lab's study of EAG2 potassium ion channel inhibitor for the treatment of Medulloblastoma.
 
Dr. Hashizume was invited to present his work Intransal delivery in the 2015 DIPG Collaborative Symposium at Ann and Robert H. Lurie Children’s Hospital of Chicago, April, 2015.
 
Dr. Hashizume was invited to present his work Epigenetic Targeting Therapy for Diffuse Intrinsic Pontine Glioma in the III Memorial “Alicia Pueyo” Workshop, Barcelona, February, 2015.

Potential Therapy Found for Incurable Pediatric Brain Tumor article details the Hashizume Lab's study of the pharmacologic inhibition of JMJD3 demethylase in DIPG.

Rintaro Hashizume, MD/PhD

Rintaro Hashizume, MD/PhD
Assistant Professor in Neurological Surgery and Biochemistry and Molecular Genetics

For more information, click here to visit our department page.

Our Mission

The research interest of our laboratory lies in identifying new effective therapies to improve the outcome of children with brain tumors. Our laboratory studies to understand the biology and molecular mechanisms that promote cancer development and progression, and would accordingly reveal potential therapeutic targets. We utilize animal model systems that faithfully recapitulate the biology and genetics of human brain tumors. Animal model systems enhance the testing of new therapeutic agents being considered for clinical trials, as well as new therapeutic approaches that bypass the blood-brain barrier, such as convection enhanced delivery and intranasal delivery.